Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life

摘要: A recent phase III trial compared the efficacy of cisplatin-topotecan (a topoisomerase I inhibitor) followed by carboplatin-paclitaxel (Arm 1) versus paclitaxel-carboplatin 2) in women with newly diagnosed stage IIB or greater ovarian cancer. There was a significantly lower response rate experimental arm to standard treatment, and less likelihood normalized CA125 within first 3 months. At 43 months follow-up, there were no significant group differences progression-free survival. also more side effects arm. The current study examined quality life (QoL) endpoints using European Organization for Research Treatment Cancer Quality Life Questionnaire C30 (EORTC QLQ-C30) cancer module, QLQ-OV28, administered prior randomization, at day 1 treatment cycles 3, 5, 7, completion last cycle, 3 6 months following chemotherapy. Global QoL, physical symptoms, fatigue, role, emotional, cognitive social function (all from EORTC improved both arms, between-arm differences. Between-group pain, insomnia, peripheral neuropathy reported while on did not differ follow-up. Nausea vomiting during after treatment. Body image differed between groups only cycle 5 (more deterioration Arm but disappeared stratified analysis global QoL debulking surgery status found effect indicating that overall improvements unrelated surgical recovery. advantage cisplatin-topotecan. This finding, combined survival conferred this combination, reaffirms as care